Study: 123I-mIBG imaging helps identify risk of arrhythmia

11/22/2009 | Doctor's Guide

A follow-up study to the ADMIRE-HF trial showed that cardiac imaging using iobenguane I-123 helps pinpoint heart-failure patients that have a low risk of fatal arrhythmic events and a higher-than-normal fatal and nonfatal arrhythmia risk. "We found that reduced myocardial sympathetic innervation on 123I-mIBG imaging is a strong and independent predictor of mortality in patients with advanced congestive heart failure," the study's lead investigator said.

View Full Article in:

Doctor's Guide

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Assistant General Counsel/Senior Corporate Counsel
Genentech
South San Francisco, CA
Senior Analyst Compliance
Edwards Lifesciences
Irvine, CA
Legal Counsel
Alcon
Fort Worth, TX
Director, Senior Legal Counsel
Alcon
Fort Worth, TX
Associate Director, Compliance Business Partner I
Boehringer Ingelheim
Ridgefield, CT